This study is testing a new treatment, VS-7375, for patients with a type of lung cancer called KRAS G12D-mutated Non-Small Cell Lung Cancer (NSCLC). This cancer type has a specific gene change called a mutation. The study will check how safe and effective VS-7375 is alone, and when combined with a drug called cetuximab.

Eligibility: Patients need to have advanced lung cancer that cannot be removed by surgery (unresectable) and have already tried treatments like chemotherapy and immune therapy. They should have a specific mutation in the KRAS gene and good organ function. Patients must have disease that can be measured using a special method called RECIST 1.1.

• The study may involve multiple visits to the clinic for check-ups and treatments.
• Patients must not have had certain other treatments or surgeries close to the study start.
• It’s important to discuss potential risks and benefits with your doctor.

Consider joining if you meet the criteria and are looking for new treatment options.